 |
This article may have been created or edited in return for undisclosed payments, a violation of Wikipedia's terms of use. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. (October 2019)
|
|
Dipen J Parekh
| |
|---|---|
| Born | 1969
Mumbai, India
|
| Nationality | American |
| Alma mater | Vanderbilt University University of Poona Memorial Sloan Kettering Cancer Center |
| Known for | Robotic surgery in Urologic-Oncology |
| Scientific career | |
| Fields | Urologic-Oncology |
| Institutions | Miller School of Medicine University of Miami |
| Website | https://doctors.umiamihealth.org/provider/Dipen+J+Parekh/525779 |
Dipen J. Parekh (born in Mumbai, India) is Chief Operating Officer at the University of Miami Health System, ChairmanofUrology and the Dr. Victor Politano Endowed Chair in Clinical Urology at the Miller School of MedicineatUniversity of MiamiinMiami.[1] He also serves as the Director of Robotic surgery at the University of Miami Health System.[2]
In 2012, he was awarded the American Urological Association Gold Cystoscope Award for his excellence in "establishing programs in urologic oncology and robotic surgery and outstanding contributions in transformative research".[3]
A native of Gujarat, India Parekh completed his MBBS at University of Poona, graduating in 1991. He underwent post graduate training in General Surgery (1995) and super-specialized in Urology (1998) from the University of Mumbai. He completed his residency (2004) in Urology from Vanderbilt University Medical Center and a fellowship (2006) at Memorial Sloan-Kettering Cancer Center in New York City. He also has a Masters in Healthcare Administration (2012) from Trinity University, Texas.[4]
He served as the Doctors Hospital at Renaissance Distinguished University Chair in Urology and Chief of Robotic Surgery and Urologic Oncology at the University of Texas Health Science Center in San Antonio from 2007 to 2012.[5]
In 2018, Parekh published the results of a clinical trial comparing Robotic Cystectomy vs. Open Cystectomy (RAZOR) in the medical journal The Lancet.[6] The RAZOR trial provided high evidence that robotic surgery is non-inferior to traditional surgery for bladder cancer.[7]
When performing partial nephrectomy, many surgeons clamp the renal artery. Urologic dogma has been that every minute of clamp time is detrimental to long-term kidney function. Therefore, Parekh led a study investigating this by performing biopsies on clamped kidneys and found no significant long-term effects with up to 60 minutes of ischemia.[8]
